Total Voting Rights and Block Listing Return

RNS Number : 9243Q

Ergomed plc

01 July 2022

 

Total Voting Rights and Block Listing Return

Total Voting Rights

Guildford, UK - 1 July 2022 : In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 30 June 2022 consisted of 49,880,029 shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

Block Listing Six Monthly Return

Name of applicant:		Ergomed plc
Name of scheme:		Ergomed plc Long Term Incentive Plan
Period of return:	From:	1 January 2022	To:	30 June 2022
Balance of unallotted securities under scheme(s) from previous return:		1,908,177
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		586,400
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1,321,777
Number and class of securities originally admitted and the date of admission		1,800,000 ordinary shares of 1p each - 2 July 2018 1,500,000 ordinary shares of 1p each - 31 December 2019 600,000 ordinary shares of 1p each - 7 July 2021
Total number of securities in issue at the end of the period		49,880,029 ordinary shares of 1p each

Name of contact:	Fiona Mundy - Director of Group Reporting
Telephone number of contact:	[phone]

ENDS

Enquiries :

Ergomed plc                                                                             Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis                                                     Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP    Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications                                   Tel: [phone]

Chris Gardner / Matthew Neal                                                   [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

TVRBBLLXLQLFBBL